Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Common Equity (2021 - 2026)

Indivior Pharmaceuticals has reported Common Equity over the past 6 years, most recently at -$144.0 million for Q1 2026.

  • For Q1 2026, Common Equity rose 49.47% year-over-year to -$144.0 million; the TTM value through Mar 2026 reached -$144.0 million, up 49.47%, while the annual FY2025 figure was -$98.0 million, 70.92% up from the prior year.
  • Common Equity for Q1 2026 was -$144.0 million at Indivior Pharmaceuticals, down from -$98.0 million in the prior quarter.
  • Over five years, Common Equity peaked at $117.0 million in Q2 2023 and troughed at -$337.0 million in Q4 2024.
  • A 5-year average of -$168.2 million and a median of -$184.0 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: plummeted 1191.67% in 2024 and later surged 70.92% in 2025.
  • Year by year, Common Equity stood at -$15.0 million in 2022, then crashed by 1126.67% to -$184.0 million in 2023, then tumbled by 83.15% to -$337.0 million in 2024, then surged by 70.92% to -$98.0 million in 2025, then tumbled by 46.94% to -$144.0 million in 2026.
  • Business Quant data shows Common Equity for INDV at -$144.0 million in Q1 2026, -$98.0 million in Q4 2025, and -$207.0 million in Q3 2025.